Patients with breast cancer and hypofunctional alleles of TLR4, TLR3, and FPR1, which interact with HMGB1, double-stranded RNA, and annexin A1, respectively, had lower rates of OS and metastasis-free survival than did their normal-allele counterparts after anthracycline-based adjuvant chemotherapy, suggesting that conventional adjuvant chemotherapy activates antitumor immunity against TAAs from dead cells via PRRs [86]. The gene discussed is FPR1; the disease is breast carcinoma.